Your session is about to expire
← Back to Search
Monoclonal Antibodies
Batoclimab for Thyroid Eye Disease
Phase 3
Recruiting
Research Sponsored by Immunovant Sciences GmbH
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Do not require immediate surgical intervention and is not planning corrective surgery/irradiation or medical therapy for TED during the course of the study.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Summary
This trial is an extension study for participants who have completed earlier studies. There are two groups in the study: an observational group and a treatment group. The observational group will look at how long the improvement
Who is the study for?
This trial is for individuals who have completed a previous study on thyroid eye disease (TED) at week 24, don't need urgent surgery, and haven't stopped using batoclimab permanently. They should not be planning any corrective procedures or other medical treatments for TED during the study.
What is being tested?
The trial has two parts: one where participants are observed to see how long their improvement in eye bulging lasts without treatment, and another where the effectiveness of batoclimab is tested by checking if it reduces eye bulging.
What are the potential side effects?
While specific side effects of batoclimab aren't listed here, similar medications can cause reactions at the injection site, muscle pain, headaches, general discomfort or flu-like symptoms.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I don't need surgery or specific treatments for thyroid eye disease during the study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Treatment CohortExperimental Treatment1 Intervention
Proptosis non-responders in feeder studies will be administered batoclimab of 680 milligram (mg) subcutaneous (SC) for 12 weeks followed by 340 mg SC for 12 weeks
Group II: Observational cohortExperimental Treatment1 Intervention
Proptosis responders in feeder studies will enter in a non-treatment observational study
Find a Location
Who is running the clinical trial?
Immunovant Sciences GmbHLead Sponsor
10 Previous Clinical Trials
1,096 Total Patients Enrolled
2 Trials studying Graves Disease
285 Patients Enrolled for Graves Disease